Biomimetic Nanophotosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy
Advanced Healthcare Materials · 2023-11 · 12 (29)
DOI: 10.1002/adhm.202301641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 13.08.2023. Verfasst von Qian Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. Hauptthemen laut MEDLINE: Pyroptosis, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Anhui Province, Scientific Research of BSKY from Anhui Medical University.
Abstract (Originalsprache)
Immunotherapy is considered to be an effective treatment for cancer and has drawn extensive interest. Nevertheless, the insufficient antigenicity and immunosuppressive tumor microenvironment often cause unsatisfactory therapeutic efficacy. Herein, a photo‐activated reactive oxygen species (ROS) amplifying system (defined as “M‐Cu‐T”) is developed to induce antitumor immune response by triggering a tumor‐specific immunogenic pyroptosis. In M‐Cu‐T, M1 macrophage membrane‐based vesicles are used for drug loading and tumor targeting, photosensitizers (meso‐tetra(4‐aminophenyl) porphyrin, TAPP) are used as a pyroptosis inducer, copper ions (Cu 2+ ) can enhance ROS‐induced pyroptosis by consuming antioxidant systems in cells. As expected, the prepared M‐Cu‐T targets enrichment into tumor cells and cascades the generation of ROS, which further induces pyroptosis through caspase 3‐mediated gasdermin E (GSDME) cleavage under laser activation. The pyroptotic cancer cells accompanying secrete related pattern molecules, induce immunogenic cell death, and activate antitumor immunity for immunotherapy. An effective tumor ablation is observed in LLC and CT26 cancer mouse models. This study provides inspiration for boosting the immunogenicity and achieving satisfactory therapeutic effects in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
- School of Life Sciences, Anhui Medical University, Hefei, 230011, China.
- Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei, 230026, China.
- College of Pharmacy, Gannan Medical University, Ganzhou, 341000, China.
ORCID-Profile: Xiaoyan He
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Anhui Province
- Scientific Research of BSKY from Anhui Medical University
- Scientific Research Level Improvement Plan of Anhui Medical University
Zitieren
APA
Wang, Q., Qin, W., Qiao, L., Gao, M., Zhou, M., Zhang, H., Sun, Q., Yao, W., Yang, T., Ren, X., Sun, G., & He, X. (2023). Biomimetic Nanophotosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy. Advanced Healthcare Materials, 12(29). https://doi.org/10.1002/adhm.202301641
Vancouver
Wang Q, Qin W, Qiao L, Gao M, Zhou M, Zhang H, et al. Biomimetic Nanophotosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy. Advanced Healthcare Materials. 2023;12(29). doi:10.1002/adhm.202301641
BibTeX
@article{Wang2023,
author = {Wang, Qian and Qin, Weiji and Qiao, Lei and Gao, Min and Zhou, Man and Zhang, Huiru and Sun, Qiuting and Yao, Wanqing and Yang, Tianhao and Ren, Xiaohe and Sun, Gengyun and He, Xiaoyan},
title = {Biomimetic Nanophotosensitizer Amplifies Immunogenic Pyroptosis and Triggers Synergistic Cancer Therapy},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {29},
doi = {10.1002/adhm.202301641}
}
EUVIMED